-
21.
公开(公告)号:US20120322786A1
公开(公告)日:2012-12-20
申请号:US13595251
申请日:2012-08-27
申请人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozafiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
发明人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozafiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
IPC分类号: A61K31/4025 , A61K31/4439 , A61K31/397 , A61K31/428 , A61K31/5377 , A61K31/40 , A61K31/422
CPC分类号: A61K31/4025 , C07C271/12 , C07D207/12 , C07D317/60 , C07D319/18 , C07D319/20 , C07D333/16 , C07D407/06 , C07D407/12 , C07D409/04 , C07D413/04 , C07D417/12
摘要: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: 用于治疗多囊肾病的化合物由结构式(I)表示:或其药学上可接受的盐。 药物组合物包含由结构式(I)表示的化合物或其药学上可接受的盐。 在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。 分别在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。
-
公开(公告)号:US4646114A
公开(公告)日:1987-02-24
申请号:US687894
申请日:1984-12-31
申请人: Charles L. Vinn , David J. Harris
发明人: Charles L. Vinn , David J. Harris
IPC分类号: H01L29/861 , H01L29/866 , H01L29/90
CPC分类号: H01L29/866
摘要: A subsurface Zener diode is provided wherein a semiconductor has formed thereon spaced apart anode and cathode regions of opposite type conductivity, such regions having opposing surface portions, and disposed beneath a surface of such semiconductor a buried region of conductivity type the same as one of such regions, such buried region extending laterally through the spaced apart regions, one of the spaced apart regions having an opposing surface portion thereof formed with a portion which protrudes towards the opposing surface portion of the other one of the spaced apart regions. With such arrangement, an electric field produced between the spaced apart regions becomes concentrated at the protrusion with the result that Zener breakdown occurs repeatedly at the same point in the semiconductor thereby reducing long term drift. Also, a Kelvin buried Zener diode is provided by forming a second laterally spaced anode region with the cathode region disposed between the pair of anode regions. One of the pair of anodes provides the force anode and the other the sense anode. The buried region extends laterally through the pair of anodes and the cathode region. The cathode region is provided with the portion which protrudes towards the force anode of the pair of anode regions and such cathode is elongated along an axis which passes between the pair of force and sense anode regions. The elongated cathode thus improves isolation between the force and sense anodes.
摘要翻译: 提供了一个次表面的齐纳二极管,其中半导体已经在其上形成了具有相反导电性的间隔开的阳极和阴极区域,这些区域具有相对的表面部分,并且在这种半导体的表面下方设置与其中之一相同的导电类型的掩埋区域 区域,这样的掩埋区域横向延伸穿过间隔开的区域,其中一个间隔开的区域具有相对的表面部分,其形成有朝向另一个间隔开的区域的相对表面部分突出的部分。 通过这样的布置,在间隔开的区域之间产生的电场在突起处变得集中,结果是在半导体的同一点处重新产生齐纳击穿从而减少长期漂移。 此外,通过形成第二横向间隔开的阳极区域,其中阴极区域设置在一对阳极区域之间,提供开尔文掩埋齐纳二极管。 一对阳极中的一个提供了力阳极和另一个阳极。 埋入区域横向延伸穿过一对阳极和阴极区域。 阴极区域设置有朝向一对阳极区域的力阳极突出的部分,并且该阴极沿着在一对力和感测阳极区域之间通过的轴线延伸。 因此,细长的阴极改善了力和感应阳极之间的隔离。
-
公开(公告)号:US4492954A
公开(公告)日:1985-01-08
申请号:US608928
申请日:1984-05-11
申请人: David J. Harris , Charles L. Vinn
发明人: David J. Harris , Charles L. Vinn
CPC分类号: H03M1/747
摘要: A digital-to-analog conversion circuitry is provided wherein a switching network is adapted to couple, or decouple, a selected one, or ones, of a plurality of identical current sources to, or from, an output bus selectively in accordance with the digital word being converted to produce an output current through an output bus having a level related to such digital word. The switching network includes: a logic network for selectively combining the plurality of bits of the digital word to produce a plurality of control signals, at least one thereof being related to a plurality of the bits of the digital word; and, a plurality of switching transistors, each one thereof having: a control (or base) electrode coupled to a corresponding one of the plurality of control signals; a first (or emitter) electrode coupled to a corresponding one of the plurality of identical current sources; and a second (or collector) electrode coupled to the output bus, such current source being coupled to, or decoupled from, such output bus selectively in accordance with the control signal fed to the control electrode of the transistor coupled to such current source, the logic network produces the plurality of control signals with substantially equal switching level variations.
摘要翻译: 提供了一种数模转换电路,其中交换网络适于将多个相同电流源中的一个或多个选择的一个或多个耦合或去耦合到输出总线或从输出总线选择性地根据数字 字被转换以通过具有与这种数字字相关的电平的输出总线产生输出电流。 交换网络包括:逻辑网络,用于选择性地组合数字字的多个位以产生多个控制信号,其至少一个与数字字的多个位相关; 以及多个开关晶体管,其中的每一个具有:耦合到所述多个控制信号中的相应一个控制信号的控制(或基极)电极; 耦合到所述多个相同电流源中的相应一个的第一(或发射极)电极; 以及耦合到输出总线的第二(或集电极)电极,这样的电流源根据馈送到耦合到这种电流源的晶体管的控制电极的控制信号选择性地耦合到这种输出总线或从该输出总线去耦, 逻辑网络产生具有基本相等的开关电平变化的多个控制信号。
-
公开(公告)号:US4343593A
公开(公告)日:1982-08-10
申请号:US115516
申请日:1980-01-25
申请人: David J. Harris
发明人: David J. Harris
CPC分类号: F01D5/282 , F01D5/30 , Y02T50/672
摘要: A turbofan engine fan blade made of composite material, and a method of making the fan, are taught. The fan blade essentially comprises an airfoil section having a root end and made of a plurality of bonded plies of composite material which are splayed and which are in a staggered condition at the root end; a two-piece platform section made of titanium or of aluminum, with one piece of the platform on each side of the airfoil section; and a steel outsert section which holds and secures the platform section to the airfoil section, with the outsert section having a triangular shaped cavity located at the root end of the airfoil section, between the splayed and staggered plies of the airfoil section. Among other advantages, the cavity eliminates the "insert plies" (or wedge) used in the prior art and the inherent disadvantages associated with such use.
摘要翻译: 教导了由复合材料制成的涡轮风扇发动机风扇叶片和制造风扇的方法。 风扇叶片基本上包括具有根端并由多个复合材料的粘合层制成的翼型部分,该复合材料层被张开并且在根端处于交错状态; 由钛或铝制成的两件式平台部分,在翼型部分的每一侧具有一个平台; 以及钢板外插部分,其将平台部分保持并固定到翼型部分,外插部分具有位于翼型部分根部的三角形空腔之间,在翼型部分的张开和交错的层之间。 除了其它优点之外,腔体消除了现有技术中使用的“插入层”(或楔形)以及与这种使用相关的固有缺点。
-
25.
公开(公告)号:US08940776B2
公开(公告)日:2015-01-27
申请号:US13595349
申请日:2012-08-27
申请人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号: A61K31/42 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/4025 , A61K31/40 , C07D277/20 , C07D277/62 , C07D261/06 , C07D405/02 , C07D271/06 , C07D207/04 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
CPC分类号: C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: 化合物由结构式(I)表示:或其药学上可接受的盐。 药物组合物包含由结构式(I)表示的化合物或其药学上可接受的盐。 治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。 受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒 戈谢的 或法布里氏病。 分别在有需要的受试者中降低血浆TNF-α,降低血糖水平,降低糖化血红蛋白水平,抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式( I)或其药学上可接受的盐。
-
26.
公开(公告)号:US20100256216A1
公开(公告)日:2010-10-07
申请号:US12601871
申请日:2008-05-30
申请人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号: A61K31/4025 , C07D405/06 , C07D207/00 , A61K31/4015
CPC分类号: C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: 化合物由结构式(I)表示:或其可药用盐。 药物组合物包含由结构式(I)表示的化合物或其药学上可接受的盐。 治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。 受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒 戈谢的 或法布里氏病。 分别在有需要的受试者中降低血浆TNF-α,降低血糖水平,降低糖化血红蛋白水平,抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式( I)或其药学上可接受的盐。
-
公开(公告)号:US20090312392A1
公开(公告)日:2009-12-17
申请号:US12387273
申请日:2009-04-30
IPC分类号: A61K31/40 , C07D207/04 , A61P43/00
CPC分类号: A61K31/397 , A61K31/40 , A61K31/445 , A61K31/498 , A61K31/5375 , C07D295/13 , C07D317/54 , C07D319/18 , C07D321/10 , Y02A50/473
摘要: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
摘要翻译: 本发明提供通过抑制GlyCer合酶抑制葡萄糖基神经酰胺(GlyCer)形成的氨基神经酰胺样化合物,从而降低糖鞘脂的含量。 本发明的化合物具有改善的GlcCer合酶抑制活性,因此可用于治疗与改变的鞘糖脂水平相关的各种病症和疾病的治疗方法。
-
公开(公告)号:US07196205B2
公开(公告)日:2007-03-27
申请号:US11091836
申请日:2005-03-28
IPC分类号: C07D405/06
CPC分类号: C07D405/06 , A61K31/4025 , C07D295/185 , C07D319/18 , C07D498/04
摘要: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
-
29.
公开(公告)号:US09272996B2
公开(公告)日:2016-03-01
申请号:US13595251
申请日:2012-08-27
申请人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozefiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
发明人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Thomas H. Jozefiak , Frederic Vinick , Yibin Xiang , John Kane , Junkai Liao
IPC分类号: A61K31/397 , A61K31/5377 , A61K31/44 , A61K31/325 , A61K31/42 , A61K31/40 , C07D207/12 , C07D271/12 , C07D317/60 , C07D319/18 , C07D333/16 , C07D407/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07C271/12 , C07D319/20 , C07D407/06
CPC分类号: A61K31/4025 , C07C271/12 , C07D207/12 , C07D317/60 , C07D319/18 , C07D319/20 , C07D333/16 , C07D407/06 , C07D407/12 , C07D409/04 , C07D413/04 , C07D417/12
摘要: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: 用于治疗多囊肾病的化合物由结构式(I)表示:或其药学上可接受的盐。 药物组合物包含由结构式(I)表示的化合物或其药学上可接受的盐。 在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。 分别在有需要的受试者中治疗多囊肾病的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。
-
30.
公开(公告)号:US08304447B2
公开(公告)日:2012-11-06
申请号:US12601871
申请日:2008-05-30
申请人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
发明人: Craig Siegel , Cecilia M. Bastos , David J. Harris , Angeles Dios , Edward Lee , Richard Silva , Lisa M. Cuff , Mikaela Levine , Cassandra A. Celatka , Frederic Vinick , Thomas H. Jozefiak , Yibin Xiang , John Kane , Junkai Liao
IPC分类号: A61K31/40 , A61K31/4025 , C07D207/04 , C07D405/02
CPC分类号: C07D417/14 , C07D295/125 , C07D319/18 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14
摘要: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: 化合物由结构式(I)表示:或其药学上可接受的盐。 药物组合物包含由结构式(I)表示的化合物或其药学上可接受的盐。 治疗有需要的受试者的方法包括向受试者施用治疗有效量的由结构式(I)表示的化合物或其药学上可接受的盐。 受试者患有2型糖尿病; 肾脏肥大或与糖尿病肾病相关的增生; 泰撒 戈谢的 或法布里氏病。 分别在有需要的受试者中降低血浆TNF-α,降低血糖水平,降低糖化血红蛋白水平,抑制葡萄糖神经酰胺合成酶和降低糖鞘醇浓度的方法包括向受试者施用治疗有效量的由结构式( I)或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-